Literature DB >> 3553950

Multiple-drug resistance in human cancer.

I Pastan, M Gottesman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3553950     DOI： 10.1056/NEJM198705283162207

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  140 in total

1.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

2.  HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.

Authors:  E Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

3.  Biology and modulation of multidrug resistance (MDR) in hematological malignancies.

Authors:  Masao Hirose
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  A mathematical model of the P-glycoprotein pump as a mediator of multidrug resistance.

Authors:  S Michelson; D Slate
Journal:  Bull Math Biol       Date:  1992-11       Impact factor: 1.758

Review 5.  Drug resistance in oncology: from concepts to applications.

Authors:  J L Cazin; P Gosselin; P Cappelaere; J Robert; A Demaille
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.

Authors:  Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

7.  PRDM1 is a tumor suppressor gene in natural killer cell malignancies.

Authors:  Can Küçük; Javeed Iqbal; Xiaozhou Hu; Phillip Gaulard; Laurence De Leval; Gopesh Srivastava; Wing Yan Au; Timothy W McKeithan; Wing C Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

8.  Dexverapamil as resistance modifier in acute myeloid leukaemia.

Authors:  R Pirker; S Zöchbauer; H Kupper; A Lassmann; A Gsur; M Frass; G Krajnik; P Knöbl; K Lechner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.

Authors:  W Scheithauer; G Kornek; M Raderer; K Koperna-Mach; C Müller; J Karner; J Kastner; C Tetzner
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.

Authors:  S Scala; A Budillon; Z Zhan; Y S Cho-Chung; J Jefferson; M Tsokos; S E Bates
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.